Browse the evidence

Shorter duration of hypertension history is an independent predictor of hypertension remission following Roux-en-Y gastric bypass surgery, with each additional year of history decreasing the odds of remission by approximately 15%.

If you are considering bariatric surgery to get off blood pressure medication, the length of time you have had high blood pressure matters. The study shows that for every year you wait, your chances of successfully stopping medication drop by about 15%. This suggests that addressing hypertension early, or seeking surgical options sooner rather than later, offers the best chance for remission.

GLP-1 receptor agonists (Liraglutid, Semaglutid) and dual agonists (Tirzepatid) produce significant weight loss (16-20%) and reduce cardiovascular/renal complications in Type 2 Diabetes, but their long-term efficacy and cost-effectiveness remain unproven.

If lifestyle changes are insufficient, GLP-1 drugs like Semaglutid offer significant weight loss (up to 20%) and heart/kidney benefits, especially for diabetics. However, they are expensive, require injections, and likely need to be taken indefinitely to maintain weight loss. Discuss cost and long-term commitment with your doctor.

SGLT-2 inhibitors, orlistat, phentermine/topiramate, metformin, tirzepatide, and Gelesis100 demonstrate varying degrees of efficacy in weight management, with SGLT-2 inhibitors showing mild but significant weight loss in non-diabetic obese patients.

Several other medications besides GLP-1 agonists can help with weight loss, including SGLT-2 inhibitors, orlistat, phentermine/topiramate, metformin, tirzepatide, and Gelesis100. Their effectiveness varies, with some showing significant weight loss and others showing mild but significant benefits. These options provide additional choices for patients who may not be candidates for or respond poorly to GLP-1 agonists.

SGLT2 inhibitors (specifically enavogliflozin and sotagliflozin) provide superior glycemic control and cardiovascular/renal benefits compared to placebo or standard care in patients with type 2 diabetes, with sotagliflozin specifically indicated for heart failure.

If you have type 2 diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors like sotagliflozin or enavogliflozin. These oral drugs are now prioritized in guidelines because they protect your heart and kidneys while lowering blood sugar.

GLP-1 receptor agonists (specifically semaglutide) produce substantial, sustained weight loss and improve health status in patients with heart failure with preserved ejection fraction (HFpEF).

For patients with HFpEF and obesity, GLP-1 agonists like semaglutide are a potent tool for weight loss and improving heart function. This treatment, combined with dietary advice, can lead to significant health improvements. Discuss this option with your cardiologist, especially if other weight loss methods have been difficult to sustain.

Visceral obesity is a critical risk factor for cardiovascular disease, often present in individuals with normal BMI, leading to underestimation of cardiovascular risk in clinical practice.

Don't rely solely on BMI. If you have a family history of heart disease, ask for a waist circumference measurement or visceral fat assessment, as 'normal weight' obesity can still cause heart attacks.

Tirzepatide (dual GLP-1/GIP agonist) produces superior weight loss compared to semaglutide in patients with type 2 diabetes.

For patients with type 2 diabetes, tirzepatide (5-15 mg weekly) may offer better weight loss (8.5-12.4%) than semaglutide (6.7%). However, it is not yet registered for obesity treatment in Poland, so access may be limited.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces greater weight loss than Semaglutide in patients with type 2 diabetes.

If you have type 2 diabetes and obesity, ask your doctor about Tirzepatide. It is a once-weekly injection that combines two hormones to help you lose more weight than Semaglutide. It starts at a low dose and increases every few weeks to reach the maximum dose.

Tirzepatide provides significant cardiovascular, hepatic, and renal benefits in obese patients, including improved lipid profiles, reduced blood pressure, and potential protection against NAFLD/NASH and CKD progression.

Beyond weight loss, Tirzepatide improves heart health by lowering blood pressure and cholesterol, and may protect the liver (NAFLD/NASH) and kidneys (CKD). These benefits are observed alongside weight loss but may also stem from direct hormonal effects.

Maintaining weight loss is significantly harder than losing it due to physiological mechanisms (AgRP neuron activation, leptin resistance) that drive weight regain, requiring sustained energy deficit and often pharmacological support.

Expect your body to fight back after you lose weight. Biological mechanisms like increased hunger signals (AgRP neurons) will try to restore your previous weight. To counter this, you need a sustained energy deficit, possibly aided by medication, and consistent lifestyle habits. Maintenance is a biological battle, not just a mental one.

Early combination therapy using low-hypoglycemia-risk agents (e.g., SGLT2 inhibitors or GLP-1 receptor agonists) combined with metformin at diagnosis is more effective than sequential stepwise therapy at maintaining glycemic targets and minimizing diabetes-related complications.

If you have just been diagnosed with Type 2 Diabetes, ask your doctor about starting with a combination of Metformin and another modern drug (like an SGLT2 inhibitor or GLP-1 agonist) right away, rather than waiting for your blood sugar to rise again. This approach keeps your blood sugar closer to normal levels for longer and protects your heart and kidneys better than starting with just one drug.

GLP-1 receptor agonists (GLP-1RA) and dual GLP-1/GIP agonists (e.g., semaglutide, tirzepatide) produce significant weight loss (up to 24.2%) and improve metabolic parameters, but they significantly increase the risk of delayed gastric emptying and perioperative pulmonary aspiration.

If you take semaglutide or tirzepatide, tell your anesthesiologist. These drugs slow down your stomach, which increases the risk of vomiting and inhaling stomach contents during surgery, even if you feel fine. You may need to stop the drug a week before surgery, or your procedure might be delayed. Do not assume standard fasting rules are enough.

Tirzepatide improves kidney function markers (eGFR decline and albuminuria) and may slow the progression of chronic kidney disease in patients with type 2 diabetes.

Tirzepatide may help protect your kidneys by slowing the decline in kidney function and reducing protein in the urine, which is beneficial for long-term kidney health in diabetes.

GLP-1 receptor agonists (GLP-1RA) and dual GLP-1/GIP agonists significantly reduce major adverse cardiovascular events (MACE), with weight loss acting as the predominant mediator of this benefit compared to blood pressure reduction alone.

If you have type 2 diabetes or obesity and are at high cardiovascular risk, GLP-1RA medications can significantly lower your risk of heart attacks and strokes. The benefit comes largely from the weight loss these drugs cause, rather than just lowering blood pressure. Discuss these options with your doctor, especially if you have resistant hypertension.

Using ambulatory blood pressure monitoring (ABPM) instead of clinic-based measurements reveals a stronger and more consistent cardiovascular benefit from GLP-1RA therapy.

If you are on GLP-1RA therapy, ask your doctor about using ambulatory blood pressure monitoring (ABPM). It may provide a more accurate assessment of your cardiovascular risk and the effectiveness of your treatment compared to standard clinic blood pressure readings.

Higher baseline insulin sensitivity is associated with greater retention of lean mass during diet-induced weight loss, but this protective effect is nullified when aerobic or resistance exercise is included in the intervention.

If you are losing weight through diet alone, your metabolic health (insulin sensitivity) dictates how much muscle you keep; those with better sensitivity lose less muscle. However, if you add exercise (especially resistance training), your baseline insulin sensitivity no longer matters for muscle preservation. Exercise protects muscle mass regardless of your metabolic profile, making it the most reliable tool for preserving lean mass during weight loss.

Discontinuation of GLP-1/GIP agonist therapy leads to significant weight regain (approx. 2/3 of lost weight within 1-2 years), necessitating chronic use.

Understand that GLP-1 therapy is likely a long-term commitment. If you stop taking the medication, you will likely regain most of the weight you lost. Plan for ongoing management rather than a fixed 'end date' for treatment.

Testosterone therapy (TTh) combined with GLP-1 receptor agonists (GLP-1RAs) and lifestyle modifications constitutes a comprehensive standard of care for obese men with functional hypogonadism, addressing metabolic, vascular, sexual, cognitive, and skeletal health.

For obese men with low testosterone, combining testosterone therapy with GLP-1RA medications (like semaglutide or liraglutide) and lifestyle changes (diet and exercise) is the most effective strategy. This approach not only boosts testosterone but also improves metabolic health, sexual function, and bone density, offering a comprehensive solution to obesity-related hormonal issues.

Dual incretin agonists (e.g., Tirzepatide) reduce total body fat mass and adipocyte size more effectively than selective GLP-1 receptor agonists (e.g., Semaglutide, Dulaglutide) by modulating both GLP-1 and GIP receptors, leading to enhanced lipolysis and reduced visceral fat.

If you are considering a dual incretin agonist like Tirzepatide, be aware that it targets two hormonal pathways (GLP-1 and GIP) rather than just one. This dual action leads to a significantly greater reduction in total body fat and visceral fat compared to single-target GLP-1 drugs, offering a more potent option for weight management.

Higher baseline circulating leptin levels in patients correlate with greater weight loss efficacy when treated with tirzepatide.

If you have obesity and type 2 diabetes, your baseline leptin level may predict how much weight you will lose with tirzepatide. Higher leptin levels are associated with greater weight loss, suggesting that combination therapy with leptin might be particularly beneficial for those with higher baseline levels.

GLP-1 receptor agonists (semaglutide 2.4 mg, tirzepatide) produce significantly greater weight loss than bariatric surgery in some metrics, but surgery remains superior for long-term durability and metabolic improvement, making GLP-1RAs a viable non-surgical alternative for patients who cannot or will not undergo surgery.

If you have obesity and want significant weight loss without surgery, ask your doctor about GLP-1 receptor agonists like semaglutide (2.4 mg weekly). These drugs work by slowing digestion and signaling fullness to your brain. They can lead to about 15% body weight loss over 16 months, which is substantial. Be prepared for potential nausea or digestive issues, which often improve over time. This is a medical treatment, not a quick fix, and works best when combined with lifestyle changes.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces the prevalence of metabolic syndrome by improving its core components: glycemic control, body weight, lipid profiles, and blood pressure.

If you have metabolic syndrome (high blood pressure, high blood sugar, high cholesterol, and excess belly fat), talk to your doctor about tirzepatide. It is a once-weekly injection that helps lower blood sugar, reduce weight, improve cholesterol, and lower blood pressure. While it can cause temporary stomach issues, these often go away, and it may offer a more comprehensive solution than lifestyle changes alone.

GLP-1 receptor agonists (GLP-1 RAs) improve glycemic control and promote weight loss in patients with type 2 diabetes and obesity through mechanisms including enhanced glucose-dependent insulin secretion, suppressed glucagon release, delayed gastric emptying, and central appetite suppression.

GLP-1 receptor agonists are highly effective medications for managing type 2 diabetes and obesity. They work by mimicking a natural hormone to increase insulin when needed, suppress glucagon, slow down digestion, and reduce appetite. This leads to significant weight loss and better blood sugar control with a lower risk of hypoglycemia compared to older diabetes drugs. Common side effects like nausea are usually temporary and can be managed by starting with a low dose and increasing it gradually. Both injectable and oral options exist, making them accessible for many patients.

Dual and triple receptor agonists (targeting GLP-1, GIP, and/or Glucagon) provide superior weight loss and glycemic control compared to selective GLP-1 receptor agonists alone.

Newer medications that target multiple hormones (GLP-1, GIP, and Glucagon) are more effective for weight loss and blood sugar control than older GLP-1 drugs alone. Drugs like tirzepatide and retatrutide have shown remarkable results, with some patients losing over 20% of their body weight. These are taken once a week and are considered a major advancement in treating obesity and diabetes.